Lipidomics: New insight into kidney disease

Advances in Clinical Chemistry

Volumn 68, Issue , 2015, Pages 153-175

  Zhao, Ying Yong ^a,b   Vaziri, Nosratola D ^b   Lin, Rui Chao ^c  

^a NORTHWEST UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Inflammation; Kidney diseases; Lipid profiling; Lipidomics; Mass spectrometry; Renal diseases; System biology

Indexed keywords

LIPID;

ANIMAL; HUMAN; KIDNEY DISEASE; LIPID METABOLISM; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; PHYSIOLOGY;

ANIMALS; HUMANS; KIDNEY DISEASES; LIPID METABOLISM; LIPIDS; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; PHYSIOLOGY;

EID: 84964258840     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2014.11.002     Document Type: Chapter

References (151)

1. Levin A., Powe N.R., Rossert J., et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007, 72:247-259.
2. Makris K., Kafkas N. Neutrophil gelatinase-associated lipocalin in acute kidney injury. Adv. Clin. Chem. 2012, 58:141-191.
3. Ling X.B., Mellins E.D., Sylvester K.G., Cohen H.J. Urine peptidomics for clinical biomarker discovery. Adv. Clin. Chem. 2010, 51:181-213.
4. Sigdel T.K., Klassen R.B., Sarwal M.M. Interpreting the proteome and peptidome in transplantation. Adv. Clin. Chem. 2009, 47:139-169.
5. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am. J. Physiol. Renal Physiol. 2006, 290:262-272.
6. Vaziri N.D., Yuan J., Ni Z., Nicholas S.B., Norris K.C. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin. Exp. Nephrol. 2012, 16:238-243.
7. Vaziri N.D. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003, 63:1964-1976.
8. Vaziri N.D. Lipotoxicity and impaired HDL-mediated reverse cholesterol/lipid transport in chronic kidney disease. J. Ren. Nutr. 2010, 20:S35-S43.
9. Vaziri N.D., Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011, 31:189-196.
10. Vaziri N.D. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin. Exp. Nephrol. 2014, 18:265-268.
11. Waldner C., Heise G., Schror K., Heering P. COX-2 inhibition and prostaglandin receptors in experimental nephritis. Eur. J. Clin. Invest. 2003, 33:969-975.
12. Hartner A., Pahl A., Brune K., Goppelt-Struebe M. Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis. Inflamm. Res. 2000, 49:345-354.
13. Tomasoni S., Noris M., Zappella S., et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J. Am. Soc. Nephrol. 1998, 9:1202-1212.
14. Zoja C., Benigni A., Noris M., et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int. 2001, 60:653-663.
15. Takano T., Cybulsky A.V., Cupples W.A., et al. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. J. Pharmacol. Exp. Ther. 2003, 305:240-249.
16. Heise G., Grabensee B., Schrör K., Heering P. Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Nephron 1998, 80:220-226.
17. Xu Z.G., Li S.L., Lanting L., et al. Relationship between 12/15-lipoxygenase and COX-2 in mesangial cells: potential role in diabetic nephropathy. Kidney Int. 2006, 69:512-519.
18. Dey A., Williams R.S., Pollock D.M., et al. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes. Res. 2004, 12:1278-1289.
19. Zhao X., Quigley J.E., Yuan J., et al. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am. J. Physiol. 2006, 290:H2187-H2195.
20. Zhou Y., Lin S., Chang H.H., et al. Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. Am. J. Hypertens. 2005, 18:530-537.
21. Zhao Y.Y., Lin R.C. Metabolomics in nephrotoxicity. Adv. Clin. Chem. 2014, 65:69-89.
22. Rosner M.H. Urinary biomarkers for the detection of renal injury. Adv. Clin. Chem. 2009, 49:73-97.
23. Fassett R.G., Venuthurupalli S.K., Gobe G.C., et al. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011, 80:806-821.
24. Lebherz-Eichinger D., Krenn C.G., Roth G.A. Keratin 18 and heat-shock protein in chronic kidney disease. Adv. Clin. Chem. 2009, 49:73-97.
25. E application in disease biomarker discovery: the discoveries in proteomics to metabolomics. Chem. Biol. Interact. 2014, 215:7-16.
26. Weiss R.H., Kim K. Metabolomics in the study of kidney diseases. Nat. Rev. Nephrol. 2011, 8:22-33.
27. Fanos V., Fanni C., Ottonello G., et al. Metabolomics in adult and pediatric nephrology. Molecules 2013, 18:4844-4857.
28. Hanna M.H., Segar J.L., Teesch L.M., et al. Urinary metabolomic markers of aminoglycoside nephrotoxicity in newborn rats. Pediatr. Res. 2013, 73:585-591.
29. Yang W.L., Bai Q., Li D.D., et al. Changes of urinary phospholipids in the chronic kidney disease patients. Biomarkers 2013, 18:601-606.
30. Subramaniam S., Fahy E., Gupta S., et al. Bioinformatics and systems biology of the lipidome. Chem. Rev. 2011, 111:6452-6490.
31. Naresh Kumar R., Sundaram R., Shanthi P., Sachdanandam P. Protective role of 20-OH ecdysone on lipid profile and tissue fatty acid changes in streptozotocin induced diabetic rats. Eur. J. Pharmacol. 2013, 698:489-498.
32. Han X., Abendschein D.R., Kelley J.G., Gross R.W. Diabetes-induced changes in specific lipid molecular species in rat myocardium. Biochem. J. 2000, 352:79-89.
33. Zhao Y.Y. Metabolomics in chronic kidney disease. Clin. Chim. Acta 2013, 422:59-69.
34. Fahy E., Subramaniam S., Murphy R.C., et al. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 2009, 50:S9-S14.
35. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
36. Coleman R.A., Lee D.P. Enzymes of triacylglycerol synthesis and their regulation. Prog. Lipid Res. 2004, 43:134-176.
37. Graham T.E. Exercise, postprandial triacylglyceridemia, and cardiovascular disease risk. Can. J. Appl. Physiol. 2004, 29:781-799.
38. Wu D.J., Zhu B.J., Wang X.D. Metabonomics-based omics study and atherosclerosis. J. Clin. Bioinforma. 2011, 1:30.
39. Traini M., Jessup W. Exploring sterol and lipid biology in the functional genomic era. Curr. Pharm. Biotechnol. 2012, 13:341-351.
40. Ivanova P.T., Milne S.B., Byrne M.O., Xiang Y., Brown H.A. Glycerophospholipid identification and quantitation by electrospray ionization mass spectrometry. Methods Enzymol. 2007, 432:21-57.
41. Farooqui A.A., Horrocks L.A., Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids 2000, 106:1-29.
42. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 2009, 15:431-440.
43. Giovane A., Balestrieri A., Napoli C. New insights into cardiovascular and lipid metabolomics. J. Cell. Biochem. 2008, 105:648-654.
44. Zhao Y.Y., Cheng X.L., Wei F., et al. Serum metabonomics study of adenine-induced chronic renal failure in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers 2012, 17:48-55.
45. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
46. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabolomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002, 1:153-161.
47. Han X., Gross R.W. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res. 2003, 44:1071-1079.
48. Spener F., Lagarde M., Geloen A., Record M. What is lipidomics?. Eur. J. Lipid Sci. Technol. 2003, 105:481-482.
49. Hu C., van der Heijden R., Wang M., et al. Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B 2009, 877:2836-2846.
50. Han X. An update on lipidomics: progress and application in biomarker and drug development. Curr. Opin. Mol. Ther. 2007, 9:586-591.
51. Lamaziere A., Wolf C., Quinn P.J. Application of lipidomics to assess lipogenesis in drug development and pre-clinical trials. Curr. Pharm. Biotechnol. 2012, 13:736-745.
52. Murphy S.A., Nicolaou A. Lipidomics applications in health, disease and nutrition research. Mol. Nutr. Food Res. 2013, 57:1336-1346.
53. Hyötyläinen T., Bondia-Pons I., Orešič M. Lipidomics in nutrition and food research. Mol. Nutr. Food Res. 2013, 57:1306-1318.
54. Miao H., Chen H., Zhang X., et al. Urinary metabolomics on the biochemical profiles in diet-induced hyperlipidemia rat using ultra-performance liquid-chromatography coupled with quadrupole time-of-flight SYNAPT high-definition mass spectrometry. J. Anal. Methods Chem. 2014, 2014:184162.
55. Chen H., Miao H., Feng Y.L., Zhao Y.Y., Lin R.C. Metabolomics in dyslipidemia. Adv. Clin. Chem. 2014, 66:101-119.
56. Rainville P.D., Stumpf C.L., Shockcor J.P., Plumb R.S., Nicholson J.K. Novel application of reversed-phase UPLC-oaTOF-MS for lipid analysis in complex biological mixtures: a new tool for lipidomics. J. Proteome Res. 2007, 6:552-558.
57. Blanksby S.J., Mitchell T.W. Advances in mass spectrometry for lipidomics. Annu Rev Anal Chem (Palo Alto, Calif) 2010, 3:433-465.
58. Li M., Yang L., Bai Y., Liu H. Analytical methods in lipidomics and their applications. Anal. Chem. 2014, 86:161-175.
59. Griffiths W.J., Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem. Soc. Rev. 2009, 38:1882-1896.
60. Grélard A., Loudet C., Diller A., Dufourc E.J. NMR spectroscopy of lipid bilayers. Methods Mol. Biol. 2010, 654:341-359.
61. Vilella F., Ramirez L.B., Simón C. Lipidomics as an emerging tool to predict endometrial receptivity. Fertil. Steril. 2013, 99:1100-1106.
62. Zhao Y.Y., Wu S.P., Liu S., Zhang Y., Lin R.C. Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chem. Biol. Interact. 2014, 220:181-192.
63. Zehethofer N., Pinto D.M. Recent developments in tandem mass spectrometry for lipidomic analysis. Anal. Chim. Acta. 2008, 627:62-70.
64. Wrona M., Mauriala T., Bateman K.P., Mortishire-Smith R.J., O'Connor D. 'All-in-One' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun. Mass Spectrom. 2005, 19:2597-2602.
65. Zhao Y.Y., Cheng X.L., Vaziri N.D., et al. UPLC-based metabonomics applications for discovering biomarkers of diseases in clinical chemistry. Clin. Biochem. 2014, 47:16-26.
66. Zhao Y.Y., Liu J., Cheng X.L., Bai X., Lin R.C. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin. Chim. Acta 2012, 413:642-649.
67. E data collection technique. Biomarkers 2012, 17:721-729.
68. E-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one. Chem. Biol. Interact. 2013, 301:31-38.
69. E. J. Pharm. Biomed. Anal. 2013, 81-82:202-209.
70. Zhang Z.H., Zhao Y.Y., Cheng X.L., et al. General toxicity of Pinellia ternata (Thunb.) Berit. in rat: a metabonomic method for profiling of serum metabolic changes. J. Ethnopharmacol. 2013, 149:303-310.
71. Peterson B.L., Cummings B.S. A review of chromatographic methods for the assessment of phospholipids in biological samples. Biomed. Chromatogr. 2006, 20:227-243.
72. Han X. Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2010, 1801:774-783.
73. Han X., Gross R.W. Shotgun lipidomics-electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 2005, 24:367-412.
74. Ståhlman M., Ejsing C.S., Tarasov K., et al. High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. J. Chromatogr. B 2009, 877:2664-2672.
75. Schiller J., Süss R., Arnhold J., et al. Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry in lipid and phospholipid research. Prog. Lipid Res. 2004, 43:449-488.
76. Li M., Zhou Z., Nie H., Bai Y., Liu H. Recent advances of chromatography and mass spectrometry in lipidomics. Anal. Bioanal. Chem. 2011, 399:243-249.
77. Zhao Y.Y., Li H.T., Feng Y.L., Bai X., Lin R.C. Urinary metabonomic study of the surface layer of poria cocos as an effective treatment for chronic renal injury in rats. J. Ethnopharmacol. 2013, 148:403-410.
78. E to unravel quantitative and qualitative information in human plasma. Rapid Commun. Mass Spectrom. 2013, 27:2195-2200.
79. E data collection technique. Process Biochem. 2012, 47:1980-1987.
80. Sun J., Baker A., Chen P. Profiling the indole alkaloids in yohimbe bark with ultra-performance liquid chromatography coupled with ion mobility quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 25:2591-2602.
81. Wilson I.D., Nicholson J.K., Castro-Perez J., et al. High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome Res. 2005, 4:591-598.
82. Chen D., Yan X., Xu J., Su X., Li L. Lipidomic profiling and discovery of lipid biomarkers in Stephanodiscus sp. under cold stress. Metabolomics 2013, 9:949-959.
83. Denoroy L., Zimmer L., Renaud B., Parrot S. Ultra high performance liquid chromatography as a tool for the discovery and the analysis of biomarkers of diseases: a review. J. Chromatogr. B 2013, 927:37-53.
84. Song J., Liu X., Wu J., et al. A highly efficient, high-throughput lipidomics platform for the quantitative detection of eicosanoids in human whole blood. Anal. Biochem. 2013, 433:181-188.
85. Bobeldijk I., Hekman M., de Vries-van der Weij J., et al. Quantitative profiling of bile acids in biofluids and tissues based on accurate mass high resolution LC-FT-MS: compound class targeting in a metabolomics workflow. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871:306-313.
86. Quehenberger O., Armando A.M., Dennis E.A. High sensitivity quantitative lipidomics analysis of fatty acids in biological samples by gas chromatography-mass spectrometry. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2011, 1811:648-656.
87. Bamba T., Lee J.W., Matsubara A., Fukusaki E. Metabolic profiling of lipids by supercritical fluid chromatography/mass spectrometry. J. Chromatogr. A 2012, 1250:212-219.
88. Kliman M., May J.C., McLean J.A. Lipid analysis and lipidomics by structurally selective ion mobility-mass spectrometry. Biochim. Biophys. Acta Mol. Cell Biol. Lip. 2011, 1811:935-945.
89. Gross R.W., Jenkins C.M., Yang J., Mancuso D.J., Han X. Functional lipidomics: the roles of specialized lipids and lipid-protein interactions in modulating neuronal function. Prostaglandins Other Lipid Mediat. 2005, 77:52-64.
90. Guo X., Lankmayr E. Multidimensional approaches in LC and MS for phospholipid bioanalysis. Bioanalysis 2010, 2:1109-1123.
91. Niemelä P.S., Castillo S., Sysi-Aho M., Orešič M. Bioinformatics and computational methods for lipidomics. J. Chromatogr. B 2009, 877:2855-2862.
92. Orešič M. Informatics and computational strategies for the study of lipids. Biochim. Biophys. Acta Mol. Cell Biol. Lip. 2011, 1811:991-999.
93. Orešič M. Bioinformatics and computational approaches applicable to lipidomics. Eur. J. Lipid Sci. Technol. 2009, 111:99-106.
94. Wood P.L. Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology 2014, 39:24-33.
95. Postle A.D. Lipidomics. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15:127-133.
96. E. J. Proteome Res. 2013, 12:692-703.
97. Jia L., Chen J., Yin P., Lu X., Xu G. Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry. Metabolomics 2008, 4:183-189.
98. Zhao Y.Y., Feng Y.L., Bai X., et al. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease. PLoS One 2013, 8:e59617.
99. Zhao Y.Y., Cheng X.L., Cui J.H., et al. Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin. Chim. Acta 2012, 413:1438-1445.
100. Liu J., Rosner M.H. Lipid abnormalities associated with end-stage renal disease. Semin. Dial. 2006, 19:32-40.
101. Keane W.F., Tomassini J.E., Neff D.R. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J. Atheroscler. Thromb. 2013, 20:123-133.
102. de Gómez Dumm N.T., Giammona A.M., Touceda L.A., Raimondi C. Lipid abnormalities in chronic renal failure patients undergoing hemodialysis. Medicina (B Aires) 2001, 61:142-146.
103. Jia L., Wang C., Zhao S., Lu X., Xu G. Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry. J. Chromatogr. B 2007, 860:134-140.
104. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 2001, 70:281-312.
105. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
106. Dill A.L., Eberlin L.S., Zheng C., et al. Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. Anal. Bioanal. Chem. 2010, 398:2969-2978.
107. Shimma S., Sugiura Y., Hayasaka T., et al. MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. J. Chromatogr. B 2007, 855:98-103.
108. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004, 64:4270-4276.
109. Del Boccio P., Raimondo F., Pieragostino D., et al. A hyphenated microLC-Q-TOF-MS platform for exosomal lipidomics investigations: application to RCC urinary exosomes. Electrophoresis 2012, 33:689-696.
110. Athar M. Oxidative stress and experimental carcinogenesis. Indian J. Exp. Biol. 2002, 40:656-667.
111. Aboagye E.O., Bhujwalla Z.M. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999, 59:80-84.
112. Alonso T., Santos E. Increased intracellular glycerophosphoinositol is a biochemical marker for transformation by membrane-associated and cytoplasmic oncogenes. Biochem. Biophys. Res. Commun. 1990, 171:14-19.
113. Zhu C., Liang Q.L., Hu P., Wang Y.M., Luo G.A. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta 2011, 85:1711-1720.
114. Guijarro C., Kasiske B.L., Kim Y., et al. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am. J. Kidney Dis. 1995, 26:152-161.
115. Lee H.S., Lee J.S., Koh H.I., et al. Intraglomerular lipid deposition in routine biopsies. Clin. Nephrol. 1991, 36:67-75.
116. Hyvönen M.E., Saurus P., Wasik A., et al. Lipid phosphotase SHIP2 downregulates insulin signalling in podocytes. Mol. Cell. Endocrinol. 2010, 328:70-79.
117. Wang Z., Jiang T., Li J., et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005, 54:2328-2335.
118. Keane W.F. The role of lipids in renal disease: future challenges. Kidney Int. Suppl. 2000, 75:S27-S31.
119. Oda H., Keane W.F. Lipids in progression of renal disease. Kidney Int. Suppl. 1997, 62:S36-S38.
120. Jimi S., Uesugi N., Saku K., et al. Possible induction of renal dysfunction in patients with lecithin: cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli. Arterioscler. Thromb. Vasc. Biol. 1999, 19:794-801.
121. Sun L., Halaihel N., Zhang W., et al. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 2002, 277:18919-18927.
122. Schleicher E., Nerlich A. The role of hyperglycemia in the development of diabetic complications. Horm. Metab. Res. 1996, 28:367-373.
123. Larkins R.G., Dunlop M.E. The link between hyperglycaemia and diabetic nephropathy. Diabetologia 1992, 35:499-504.
124. Ayo S.H., Radnik R., Garoni J.A., Troyer D.A., Kreisberg J.I. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am. J. Physiol. 1991, 261:F571-F577.
125. Li M., Feng B., Liang Y., et al. Lipid profiling of human plasma from peritoneal dialysis patients using an improved 2D (NP/RP) LC-QToF MS method. Anal. Bioanal. Chem. 2013, 405:6629-6638.
126. Stenvinkel P., Holmeberg I., Heimbürger O., Diczfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol. Dial. Transplant. 1998, 13:2594-2600.
127. Cheng L.T., Tang W., Wang T. Strong association between volume status and nutritional status in peritoneal dialysis patients. Am. J. Kidney Dis. 2005, 45:891-902.
128. 2-isoprostanes: sensitive biomarkers of oxidative stress in vitro and in vivo: a gas chromatography-mass spectrometric approach. Methods Mol. Biol. 2009, 580:3-16.
129. Jia L., Wang C., Kon H., Cai Z., Xu G. Plasma phospholipid metabolic profiling and biomarkers of mouse IgA nephropathy. Metabolomics 2006, 2:95-103.
130. Arrizabalaga P., Sole M., Abellana R. Tubular and interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy. Am. J. Nephrol. 2003, 23:121-128.
131. Patterson N.H., Thomas A., Chaurand P. Monitoring time-dependent degradation of phospholipids in sectioned tissues by MALDI imaging mass spectrometry. J. Mass Spectrom. 2014, 49:622-627.
132. Fröhlich S., Putz B., Schachner H., et al. Renopathological microstructure visualization from formalin fixed kidney tissue by matrix-assisted laser/desorption ionization-time-of-flight mass spectrometry imaging. Balkan J. Med. Genet. 2012, 15:13-16.
133. Kaneko Y., Obata Y., Nishino T., et al. Imaging mass spectrometry analysis reveals an altered lipid distribution pattern in the tubular areas of hyper-IgA murine kidneys. Exp. Mol. Pathol. 2011, 91:614-621.
134. Coppo R., Fonsato V., Balegno S., et al. Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int. 2010, 77:417-427.
135. Robinson D.R., Tateno S., Patel B., et al. Dietary marine lipids after the course of autoimmune disease. Prog. Clin. Biol. Res. 1988, 282:295-303.
136. Fukui M., Nakamura T., Ebihara I. ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 1992, 41:1520-1527.
137. Lynch J.J., Ferro T.J., Blumenslock F.A. Increased endothelial albumin permeability mediated by protein kinase C activation. J. Clin. Invest. 1990, 85:1991-1998.
138. Schmitz P.G., Zhang K. 1994 Expression of protein kinase C-alpha in the remnant kidney proposed role in potentiating glomerular capillary hypertension. J. Am. Soc. Nephrol. 1994, 5:611.
139. Chen S., Cohen M.P., Lautenslager G.T., et al. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int. 2001, 59:673-681.
140. Liu G., Han F., Yang Y., et al. Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of rapamycin. Nephrol. Dial. Transplant. 2011, 26:1493-1502.
141. Yang Y., Wang J., Qin L., et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am. J. Nephrol. 2007, 27:495-502.
142. Ueda N., Kaushal G.P., Hong X., et al. Role of enhanced ceramide generation in DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells. Kidney Int. 1998, 54:399-406.
143. Basnakian A.G., Ueda N., Hong X., et al. Ceramide synthase is essential for endonuclease-mediated death of renal tubular epithelial cells induced by hypoxia-reoxygenation. Am. J. Physiol. Renal Physiol. 2005, 288:F308-F314.
144. Itoh Y., Yano T., Sendo T., et al. Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury. Kidney Int. 2006, 69:288-297.
145. Datta P.K., Koukouritaki S.B., Hopp K.A., et al. Heme oxygenase-1 induction attenuates inducible nitric oxide synthase expression and proteinuria in glomerulonephritis. J. Am. Soc. Nephrol. 1999, 10:2540-2550.
146. Toda N., Takahashi T., Mizobuchi S., et al. Tin chloride pretreatment prevents renal injury in rats with ischemic acute renal failure. Crit. Care Med. 2002, 30:1512-1522.
147. Hassan I.R., Gronert K. Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury. J. Immunol. 2009, 182:3223-3232.
148. Levy B.D., Kohli P., Gotlinger K., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 2007, 178:496-502.
149. Mustad V.A., Demichele S., Huang Y.S., et al. Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse. Metabolism 2006, 55:1365-1374.
150. 2 on chemotherapeutic-induced death and phospholipid profiles in renal cells. Biochem. Pharmacol. 2005, 70:1697-1706.
151. Masood M.A., Rao R.P., Acharya J.K., Blonder J., Veenstra T.D. Quantitation of multiple sphingolipid classes using normal and reversed-phase LC-ESI-MS/MS: comparative profiling of two cell lines. Lipids 2012, 47:209-226.